ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
8 001,80
-0,48%
Dow Jones
38 798,99
-0,22%
DAX
18 557,27
-0,48%
Brent Oil
79,395
0,00%
Bitcoin
69 461,96
0,19%
Registration Strip Icon for alerts Inscrivez-vous pour des alertes en temps réel, un portefeuille personnalisé et des mouvements de marché.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Castle Biosciences Inc (CSTL)

  7. Castle Biosciences Inc (CSTL) Actualités

CSTL Castle Biosciences Inc

23,15
0,12 (0,52%)
08 Juin 2024 - Fermé
Retardé de 15 minutes
Nom Action Symbole Action Marché Type
Castle Biosciences Inc CSTL NASDAQ Action ordinaire
  Variation Action Variation Action% Cours Dernier Dernier échange
Upgrade Icon
0,12 0,52% 23,15 01:34:02
Ouverture Plus Bas Plus Haut Prix de clôture Clôture Veille
22,4601 22,4601 23,2599 23,15 23,03
plus d'informations sur les cotations »

Actualités Recentes

Date Heure Source Titre
05/6/202400:52EDGAR2Form 4 - Statement of changes in beneficial ownership of..
30/5/202422:30BWCastle Biosciences to Present New Data at 2024 ASCO® Annual..
29/5/202422:44EDGAR2Form 4 - Statement of changes in beneficial ownership of..
29/5/202422:41EDGAR2Form 4 - Statement of changes in beneficial ownership of..
29/5/202422:30BWNew Publication Shows DecisionDx®-SCC Identifies High-Risk..
28/5/202422:18EDGAR2Form 4 - Statement of changes in beneficial ownership of..
28/5/202422:15EDGAR2Form 4 - Statement of changes in beneficial ownership of..
28/5/202422:13EDGAR2Form 4 - Statement of changes in beneficial ownership of..
28/5/202422:08EDGAR2Form 4 - Statement of changes in beneficial ownership of..
24/5/202422:27EDGAR2Form 8-K - Current report
15/5/202413:00BWCastle Biosciences to Present at the Leerink Partners..
14/5/202413:00BWCastle Biosciences Expands Evidence Supporting the..
10/5/202421:14EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
10/5/202413:00BWCastle Biosciences’ IDgenetix® Test Receives 2024 MedTech..
08/5/202422:30BWLargest Prospective Study to Date Further Supports..
03/5/202413:00BWDecisionDx®-SCC Significantly Improves Prediction Accuracy..
02/5/202422:05BWCastle Biosciences Reports First Quarter 2024 Results
30/4/202422:30BWCastle Biosciences Kicks off Skin Cancer Awareness Month..
11/4/202413:00BWCastle Biosciences to Release First Quarter 2024 Financial..
10/4/202423:00BWCastle Biosciences Celebrates Esophageal Cancer Awareness..
10/4/202413:00BWCastle Biosciences’ Chief Financial Officer Frank Stokes..
04/4/202422:30BWPresentations at EADO Highlight Potential Impact of Castle..
02/4/202413:00BWCastle Biosciences to Present at the 23rd Annual Needham..
27/3/202422:00BWCastle Biosciences Announces Updates to its Board of..
25/3/202412:00BWCastle Biosciences Earns a Top Workplaces USA Award for the..
22/3/202421:30BWLong-term Outcomes Data Shared at SSO 2024 Show That..
19/3/202412:00BWLeading Squamous Cell Carcinoma Practitioners Publish..
15/3/202421:30BWNew Study Shows that the Drug-Drug Interactions and..
12/3/202412:00BWCastle Biosciences to Present at the KeyBanc Capital Markets..
08/3/202422:30BWCastle Biosciences to Present New Data Highlighting the..
07/3/202413:00BWIn Novel Cohort, New Data Confirms DecisionDx®-SCC Provides..
07/3/202400:07EDGAR2Form 4 - Statement of changes in beneficial ownership of..
07/3/202400:04EDGAR2Form 4 - Statement of changes in beneficial ownership of..
07/3/202400:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
28/2/202423:15EDGAR2Form S-8 - Securities to be offered to employees in employee..
28/2/202422:05BWCastle Biosciences Reports Fourth Quarter and Full-Year 2023..
26/2/202413:00BWStudy Finds DecisionDx®-Melanoma Significantly Improves the..
07/2/202413:00BWCastle Biosciences to Release Fourth Quarter and Full-Year..
18/1/202413:00BWNew Study Highlights Significant Potential Medicare Savings..
14/1/202410:30BWCastle Biosciences Presents Data Supporting the Utility of..
09/1/202413:00BWCastle Biosciences’ Chief Operating Officer Kristen..
08/1/202413:04EDGAR2Form 8-K - Current report
08/1/202402:00BWCastle Biosciences Announces Preliminary Fourth Quarter and..
04/1/202423:16EDGAR2Form 4 - Statement of changes in beneficial ownership of..
03/1/202422:11EDGAR2Form 4 - Statement of changes in beneficial ownership of..
20/12/202313:00BWCastle Biosciences Reports Inducement Grants Under Nasdaq..
13/12/202301:39EDGAR2Form 4 - Statement of changes in beneficial ownership of..
13/12/202301:33EDGAR2Form 4 - Statement of changes in beneficial ownership of..
13/12/202301:28EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04/12/202322:50EDGAR2Form S-8 - Securities to be offered to employees in employee..

Dernières Valeurs Consultées

NASDAQ
CSTL
Castle Biosciences
COIN
JAMUST
Geojam
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés